Eagle Asset Management’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Eagle Asset Management’s Portfolio ICPT Stock Details ICPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-269,427	Closed	-$12.6M	–	606
2020 Q2	$12.6M	Buy	+269,427	New	+$20.8M	0.07%	247
2019 Q1	–	Sell	-285,666	Closed	-$28.8M	–	639
2018 Q4	$28.8M	Buy	+285,666	New	+$29.6M	0.18%	199
2014 Q2	–	Sell	-93,021	Closed	-$30.7M	–	672
2014 Q1	$30.7M	Buy	+93,021	New	+$31.4M	0.17%	188

Other funds holding ICPT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

SCM

Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return

Eagle Asset Management's ICPT Position: Q3 2020 in Review

Eagle Asset Management sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q3 2020, closing a stake of 269,427 shares — an estimated $12.6M sold.

Eagle Asset Management first reported a position in ICPT in Q1 2014 and held it in 3 quarters. The position peaked at $30.7M in Q1 2014. 177 funds tracked by Wall St. Rank hold ICPT as of Q3 2020.

Eagle Asset Management reported no remaining Intercept Pharmaceuticals, Inc. position as of Q3 2020 after selling out during the quarter.
Eagle Asset Management sold 269,427 Intercept Pharmaceuticals, Inc. shares in Q3 2020, an estimated $12.6M.
Eagle Asset Management first reported a position in Intercept Pharmaceuticals, Inc. in Q1 2014 and held it in 3 quarters.
Eagle Asset Management's Intercept Pharmaceuticals, Inc. position peaked at $30.7M in Q1 2014.
177 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q3 2020.

Based on Eagle Asset Management's 13F filing for Q3 2020, filed 12 Nov 2020.